Who are Insulin aspart SAR341402's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tresiba, Levemir, Apidra, Novolog, Lantus, Humalog.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/insulin-aspart-sar341402.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Insulin aspart SAR341402 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Insulin aspart SAR341402 (Insulin aspart SAR341402) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rapid-acting insulin analog. Area: Diabetes.

phase 3 Rapid-acting insulin analog Insulin receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Insulin aspart SAR341402 (Insulin aspart SAR341402) — Sanofi. Insulin aspart SAR341402 is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulin aspart SAR341402 TARGET	Insulin aspart SAR341402	Sanofi	phase 3	Rapid-acting insulin analog	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rapid-acting insulin analog class)

Eli Lilly and Company · 12 drugs in this class
Sanofi · 6 drugs in this class
Novo Nordisk A/S · 4 drugs in this class
Rigshospitalet, Denmark · 2 drugs in this class
Mountain Diabetes and Endocrine Center · 1 drug in this class
Mylan Inc. · 1 drug in this class
Nanjing First Hospital, Nanjing Medical University · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Oxford University Hospitals NHS Trust · 1 drug in this class
Tel-Aviv Sourasky Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Insulin aspart SAR341402 — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-aspart-sar341402. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab